Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06252649 · ClinicalTrials.gov registry record · Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
A Phase 3 study of Metastatic Colorectal Cancer, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT06252649 is a Phase 3 study of Metastatic Colorectal Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 450 participants, above the 176-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (156% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT06252649, a Phase 3 study of Metastatic Colorectal Cancer, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
Conditions Studied
Interventions
- DRUG Sotorasib
- DRUG Panitumumab
- DRUG FOLFIRI Regimen
- DRUG Bevacizumab-awwb
Study Locations (20)
California
- Providence Saint Jude Medical Center - Fullerton
- City of Hope National Medical Center - Long Beach
- Cancer and Blood Research Center, LLC - Los Alamitos
- California Research Institute - Los Angeles
Florida
- Cancer Specialists of North Florida - Southpoint - Jacksonville
- D and H Cancer Research Center - Margate
- Mid Florida Hematology and Oncology Centers PA - Orange City
- Boca Raton Clinical Research Medical Center Inc - Plantation
Illinois
- Insight Research Institute - Chicago
- Hope and Healing Cancer Services - Hinsdale
- Orchard Healthcare Research Inc - Skokie
Michigan
- Henry Ford Health System - Detroit
- Cancer and Hematology Centers of Western Michigan - Grand Rapids
Arizona
- Ironwood Cancer and Research Centers Scottsdale - Chandler
Connecticut
- Norwalk Hospital - Norwalk
Georgia
- Georgia Cancer Specialists - Atlanta
Kentucky
- Pikeville Medical Center - Pikeville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2024-07-17 |
| Est. Completion | 2031-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06252649
The ClinicalTrials.gov registry entry for NCT06252649 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 176-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (156% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Sotorasib is the first listed.
NCT06252649 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06252649 about?
NCT06252649 is a clinical study titled "Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation". The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
What is the current status of trial NCT06252649?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2024-07-17. Estimated completion is 2031-08-31.
What conditions does trial NCT06252649 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT06252649?
The interventions under investigation include: Sotorasib (DRUG), Panitumumab (DRUG), FOLFIRI Regimen (DRUG), Bevacizumab-awwb (DRUG).
Who is sponsoring clinical trial NCT06252649?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06252649 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
RECRUITING · Phase 3
-
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
ACTIVE NOT RECRUITING · Phase 3
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.